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ABSTRACT
Helicobacter pylori is associated with many clinical 
conditions including gastric and extra-gastric 
pathologies. Prevalence is high in most Sub-
Saharan African countries where data is available. 
Its association with diseases is not fully established 
in the region. Due to emergence of antibiotic 
resistance, the conventional triple and quadruple 
therapies using proton pump inhibitors and 
antimicrobial agents are now obsolete. Many 
Western countries have revised their therapeutic 
guidelines with a common recommendation to 
determine prior patient exposure to antibiotics, 
determine local drug resistance patterns and 
eradication rates, use higher doses of proton pump 
inhibitors, and include bismuth sub-citrate if 
clarithromycin resistance is suspected. Sub-Saharan 
African countries lack data on these making it 
difficult to apply these recommendations. The 
countries in Sub-Saharan Africa need to recognize 
the growing clinical importance of H. pylori and 
initiate programs to determine its local 
epidemiology, drug resistance, and its association 
with diseases in the region. Collaborative effort is 
required to achieve these goals and establishment of 
regional reference laboratories for monitoring drug 
resistance may be helpful.
INTRODUCTION
Helicobacter pylori, a gram-negative organism that 
infects the gastric mucosa, is associated with several 
gut disorders such as peptic ulcer disease, chronic 
1-5gastritis, and gastric cancers . Its discovery led to 
dramatic changes in the management of peptic ulcer 
disease globally, and many countries recorded 
6significant decreases in peptic ulcer incidence . The 
records notwithstanding, in many developing 
countries, the prevalence of Helicobacter pylori 
infection remains high, while the actual values in 
most Sub-Saharan African countries are unknown. 
Available data from some of the African countries 
7, 8indicate very high prevalence values . To a large 
9extent, this infection is neglected in the region , and 
the extent of its contribution to diseases in Africa is 
not clear. 
Helicobacter pylori infection is commonly 
managed with a combination of antibiotics and 
gastric acid lowering drugs. Therapeutic guidelines 
in most countries recommend either triple therapy 
using two antibiotics plus a proton pump inhibitor 
such as omeprazole or two antibiotics plus H -2
receptor blocker such as ranitidine and cimetidine. 
Quadruple therapy involving the use of three 
antimicrobials and an acid reducing agent may be 
used in cases of failure with triple therapy. However, 
the effectiveness of these regimens is complicated 
by the emergence of drug resistance to most 
10-14recommended antibiotics . To this effect, most 
regions of the world, apart from Sub-Saharan Africa, 
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have revised their treatment guidelines for H. pylori 
associated diseases. The objectives of this article are 
to present the current global perspectives on H. 
pylori treatment in the presence of emerging 
antibiotic resistance, and to highlight the issues and 
challenges associated with the pharmacotherapy of 
H. pylori in Africa.
EPIDEMIOLOGY
The global prevalence of H. pylori infections is 
15-17estimated to be more than 50 % . There exists 
18great disparity in regional prevalence however , 
with the advanced countries such as Switzerland and 
Denmark having values below 30 % while 
developing countries like Pakistan, Nepal, and 
15Libya have values exceeding 75 % . Countries in 
Oceania (such as Australia and New Zealand) appear 
to have the least prevalence values. Significant intra-
regional variations also occur. Sub-Saharan African 
countries have the greatest burden of H. pylori 
infections, with many countries recording 
prevalence values higher than 70 %. For example, 
reported prevalence for the Republic of South Africa 
15, 19range from 51 % to 77.6 % , Nigeria 83 % – 92 %, 
Benin 70 % – 81 %, and Democratic Republic of the 
15 20Congo 70 % – 81 % . Eusebi and others  recently 
presented a comprehensive review of the global 
prevalence of H. pylori infections. 
Most H. pylori infections are acquired in 
21childhood . The social determinants of this 
infection are similar to those associated with other 
neglected tropical diseases and other endemic 
diseases of poverty. These include poor personal and 
environmental hygiene, poor drinking water quality, 
22and overcrowded accommodation . The precise 
routes of disease transmission are not certain, but 
evidence suggests that acquisition is usually via the 
oral-oral or fecal-oral transmission, drinking water 
23-27and often perpetuates within the family circle . 
Although H. pylori infection has ostensibly been 
identified as risk factor for gastro-duodenal ulcer, 
chronic gastritis, and gastric cancer, the association 
between these disease and H. pylori infection is 
unpredictable: only a small proportion of H. pylori 
infected individuals develop disease, and 
manifestation of disease as a result of infection 
appears to be determined by multiple factors 
28-33including a geographical component . For 
22example, Aitila and colleagues  studied children 
with gastrointestinal complaints in Western Uganda 
and observed a H. pylori prevalence of 23.4 % 
compared to 44.3 % in another similar study in the 
general population in Kampala. The phenomenon 
initially described as the “African enigma,” whereby 
seropositivity does not correlate with disease 
burden, has now been observed in other areas of the 
34-37world . This has been attributed to existence of 
strain to strain variation in the presence of certain 
pathogenicity factors. 
PATHOGENICITY 
The current knowledge of the spectrum of diseases 
caused by H. pylori infection has expanded. 
Emerging evidence shows that, in addition to well 
established association between H. Pylori infection 
and gastrointestinal diseases such as chronic gastritis 
and duodenitis, gastric and duodenal ulcers, and 
gastric mucosa-associated lymphoid tissue (MALT) 
38, 39lymphoma , H. pylori is now known to be 
associated with several extra-gastric diseases such as 
cardiovascular, respiratory, neural, autoimmune, 
40-48and metabolic diseases . Several articles present 
49-52comprehensive reviews on this topic . 
The pathogenicity of H pylori has been linked to the 
53,55presence of two genes, cagA and vacA . The cagA 
gene is a member of the cag pathogenicity island 
(PAI) which encodes the CagA protein responsible 
for induction of interleukins and nuclear factors 
3, 56, 57associated with H. pylori induced diseases . The 
vacA gene encodes the vacoulating cytotoxin, VacA. 
VacA also has strong association with H. pylori 
58-60pathogenicity . 
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P H A R M A C O T H E R A P Y A N D  D R U G  
RESISTANCE
The conventional treatments for H. pylori infections 
comprise a proton pump inhibitor in combination 
with antibiotics. Most guidelines recommend triple 
therapy with Clarithromycin, metronidazole, and/or 
amoxicillin, with a proton pump inhibitor as first line 
treatment. A quadruple therapy incorporating a 
fourth agent such as Bismuth compounds is also 
highly recommended in cases of therapeutic failure. 
Reduction of gastric acidity is well accepted practice 
in the treatment of H. pylori infections. Not only is 
this desirable for the healing of any ulcers, but the 
higher gastric pH has been reported to reduce H. 
pylori load and increase the susceptibility of the 
61organism to antibiotics . The proton pump 
inhibitors take the lead in this respect and a higher 
dosage (twice daily) regiment is reported to be more 
effective than the standard (once daily) regiment. 
Recommended proton pump inhibitors include 
omeprazole (20 mg), rabeprazole (20 mg), 
lansoprazole (30 mg), esmoprazole (40 mg), and 
pantoprazole (40 mg). However, genetic differences 
may affect individual response to proton pump 
61inhibitors , and chronic use of proton pump 
inhibitors is associated with risk of gastritis and 
62-66gastric cancer . Histamine (H ) receptor blockers 2
may be used as alternatives to proton pump 
inhibitors but their efficacy has been reported to be 
67less than those of proton pump inhibitors . Another 
class of gastric acid suppressants, potassium-
competitive acid blockers exemplified by 
Vonoprazan, has been recommended as substitute to 
68proton pump inhibitors for H. pylori treatment . 
Vonoprazan (1-[5-(2-Fluorophenyl)-1-(pyridin-3-
ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine 
Monofumarate (TAK-438), C H FN O S), 1 7 1 6 3 2
competitively and reversibly block H+/K+ ATPase. 
Its efficacy in the treatment of H. pylori associated 
conditions is reported to equal those of proton pump 
69inhibitors, but it has its own set of adverse effects . 
Clarithromycin occupies a first-line position in the 
antimicrobial treatment of H. pylori infections. 
Tr iple  or  quadruple  therapies  that  are  
clarithromycin-based have demonstrated high 
efficacies in the eradication of H. pylori infections, 
70, 71especially when metronidazole is included .
However, the emergence of clarithromycin resistant 
H. pylori strains is now a global phenomenon that 
challenges the a priori established therapeutic 
guidelines for the clinical management H. pylori 
72-74infections . Resistance to other recommended 
antibiotics such as metronidazole, levofloxacin, and 
amoxicillin, are now commonly reported across the 
75-77globe . Bismuth subcitrate is increasingly 
recommended for inclusion as part of first line, 
second line, or rescue therapy in cases of 
demonstrated drug resistance and shows significant 
78-82improvement in eradication rates .  
The global emergence of H. pylori resistant strains 
has resulted in revisions of standard therapeutic 
guideline for its eradication. These modifications 
include the 'Kyoto Global Consensus on 
Helicobacter pylori gastritis' which presented 
comprehensive guide for the clinical management of 
83H. pylori gastritis , the 'Toronto Consensus for the 
Treatment of Helicobacter pylori Infection in 
84Adults' , and the 'Guidelines for the management of 
Helicobacter pylori infection in Italy: The III 
85Working Group Consensus Report 2015' . These 
consensus statements have many things in common 
which include the need to determine previous 
antibiotic exposure, knowledge of local/regional  H. 
pylori drug resistance patterns and eradication rates, 
and the inclusion of bismuth sub-citrate in 
therapeutic regimens if clarithromycin resistance is 
suspected. The consensus statements also 
recommended using higher doses of proton pump 
inhibitors e.g. twice daily dosing instead of the usual 
once daily dosing and avoiding repeating the same 
regimen that failed. Table 1 presents a summary of 
these consensus statements.
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Other therapeutic regimens have also emerged such 
86as sequential and concomitant therapy . In a typical 
sequential therapy, rabeprazole (a proton pump 
inhibitor) and amoxicillin were initially given for 5-
7 days followed by rabeprazole, clarithromycin and 
metronidazole for a further 5-7 days. Concomitant 
therapy utilized rabeprazole, amoxicillin, 
clarithromycin, and metronidazole for 14 days. 
These recommendations are appropriate for western 
developed countries that have ample information on 
H. pylori drug resistance, and where use of the 
relevant antibiotics is well regulated and 
documented. In sub-Saharan African, antibiotics use 
is not stringently regulated partly because of the 
many cases of bacterial infections. In a recent 
review, Tadasse and colleagues noted the lack of 
recent antimicrobial resistance data in many Sub-
Saharan African countries. Data from few studies 
indicated high levels of resistance to antimicrobial 
87agents . Specific H. pylori drug resistance data are 
also not widely available for many Sub-Saharan 
African countries. The few available data show 
alarming high rates of H. pylori resistance to 
13, 77, 88recommended antibiotics .  In a systematic 
review of reports from Africa, Jaka and colleagues 
reported 29.2 % resistance to clarithromycin, 75.8 % 
resistance to metronidazole, and 72.6 % resistance to 
88amoxicillin .
Table 1. Summary of Current Consensus 
Statements on H. pylori Treatment
CONCLUSION AND RECOMMENDATIONS
Sub-Saharan Africa lacks reliable data on the 
regional and intra-country prevalence of H. pylori 
infections. The association between H. pylori 
positivity and disease is not fully established in the 
region. There is also no current report on the 
appraisal of the efficacy of the triple and quadruple 
therapeutic strategies adopted by many countries. 
Information on drug resistance is scanty. The few 
available reports suggest a high rate of drug 
resistance. For these reasons, recommending a 
evidence-based therapeutic strategies is difficult. 
The way forward for Africa is to recognize the 
clinical importance of this neglected pathogen in the 
region. More studies are needed to provide national 
and regional epidemiological data including data on 
drug resistance and disease association with H 
pylori infection in Sub-Saharan Africa.  Regional 
diagnostic laboratories should be established to test 
H pylori susceptibility. A Pan-African conference on 
Helicobacter pylori could provide opportunity to 
brain-storm on H pylori pathogenicity, prevalence 
and drug resistance in Africa.
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